# This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer

> **NCT03099174** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 133 (actual)

## Conditions studied

- Neoplasms
- Breast Neoplasms

## Interventions

- **DRUG:** Xentuzumab
- **DRUG:** Abemaciclib
- **DRUG:** Letrozole
- **DRUG:** Anastrozole
- **DRUG:** Fulvestrant
- **DRUG:** Abemaciclib

## Key facts

- **NCT ID:** NCT03099174
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-04
- **Primary completion:** 2023-05-31
- **Final completion:** 2024-05-16
- **Target enrollment:** 133 (ACTUAL)
- **Last updated:** 2025-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03099174

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03099174, "This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03099174. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*